Selective PPAR modulator
A selective PPAR modulator (SPPARM) is a selective receptor modulator of the peroxisome proliferator-activated receptor (PPAR).{{cite journal |last1=Fruchart |first1=Jean-Charles |last2=Santos |first2=Raul D. |last3=Aguilar-Salinas |first3=Carlos |last4=Aikawa |first4=Masanori |last5=Al Rasadi |first5=Khalid |last6=Amarenco |first6=Pierre |last7=Barter |first7=Philip J. |last8=Ceska |first8=Richard |last9=Corsini |first9=Alberto |last10=Després |first10=Jean-Pierre |last11=Duriez |first11=Patrick |last12=Eckel |first12=Robert H. |last13=Ezhov |first13=Marat V. |last14=Farnier |first14=Michel |last15=Ginsberg |first15=Henry N. |last16=Hermans |first16=Michel P. |last17=Ishibashi |first17=Shun |last18=Karpe |first18=Fredrik |last19=Kodama |first19=Tatsuhiko |last20=Koenig |first20=Wolfgang |last21=Krempf |first21=Michel |last22=Lim |first22=Soo |last23=Lorenzatti |first23=Alberto J. |last24=McPherson |first24=Ruth |last25=Nuñez-Cortes |first25=Jesus Millan |last26=Nordestgaard |first26=Børge G. |last27=Ogawa |first27=Hisao |last28=Packard |first28=Chris J. |last29=Plutzky |first29=Jorge |last30=Ponte-Negretti |first30=Carlos I. |last31=Pradhan |first31=Aruna |last32=Ray |first32=Kausik K. |last33=Reiner |first33=Željko |last34=Ridker |first34=Paul M. |last35=Ruscica |first35=Massimiliano |last36=Sadikot |first36=Shaukat |last37=Shimano |first37=Hitoshi |last38=Sritara |first38=Piyamitr |last39=Stock |first39=Jane K. |last40=Su |first40=Ta-Chen |last41=Susekov |first41=Andrey V. |last42=Tartar |first42=André |last43=Taskinen |first43=Marja-Riitta |last44=Tenenbaum |first44=Alexander |last45=Tokgözoğlu |first45=Lale S. |last46=Tomlinson |first46=Brian |last47=Tybjærg-Hansen |first47=Anne |last48=Valensi |first48=Paul |last49=Vrablík |first49=Michal |last50=Wahli |first50=Walter |last51=Watts |first51=Gerald F. |last52=Yamashita |first52=Shizuya |last53=Yokote |first53=Koutaro |last54=Zambon |first54=Alberto |last55=Libby |first55=Peter |title=The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential |journal=Cardiovascular Diabetology |date=4 June 2019 |volume=18 |issue=1 |pages=71 |doi=10.1186/s12933-019-0864-7 |pmid=31164165 |pmc=6549355 |issn=1475-2840 |doi-access=free }}{{cite journal |last1=Fruchart |first1=Jean-Charles |last2=Hermans |first2=Michel P. |last3=Fruchart-Najib |first3=Jamila |last4=Kodama |first4=Tatsuhiko |title=Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel? |journal=Current Atherosclerosis Reports |date=3 January 2021 |volume=23 |issue=1 |pages=3 |doi=10.1007/s11883-020-00897-x |pmid=33392801 |pmc=7779417 |language=en |issn=1534-6242}}{{cite journal |last1=Balint |first1=B. L. |last2=Nagy |first2=L. |title=Selective modulators of PPAR activity as new therapeutic tools in metabolic diseases |journal=Endocrine, Metabolic & Immune Disorders Drug Targets |date=March 2006 |volume=6 |issue=1 |pages=33–43 |doi=10.2174/187153006776056620 |pmid=16611163 |url=https://pubmed.ncbi.nlm.nih.gov/16611163/ |issn=1871-5303}} Examples include SPPARMs of the PPARγ, BADGE, EPI-001, INT-131, MK-0533, and S26948.